Evidence map›Paper›PMID 32450093›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2020

Reactive oxygen species and enzyme dual-responsive biocompatible drug delivery system for targeted tumor therapy.

Ning Zhao, Bingbing Ding, Ying Zhang, Jessica L Klockow, Ken Lau, Frederick T Chin, Zhen Cheng, Hongguang Liu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Crosstalk between G-quadruplex and ROS.Cell death & disease · 2023
    Review
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Ning ZhaoDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University, Palo Alto, California 94305, United States. Electronic address: zhaoning@stanford.edu.
Bingbing DingDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University, Palo Alto, California 94305, United States.
Ying ZhangInstitute of Molecular Medicine, College of Life and Health Sciences, Northeastern University, Shenyang 110000, PR China.
Jessica L KlockowDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University, Palo Alto, California 94305, United States.
Ken LauDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University, Palo Alto, California 94305, United States.
Frederick T ChinDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University, Palo Alto, California 94305, United States.
Zhen ChengDepartment of Radiology, Molecular Imaging Program at Stanford, Stanford University, Palo Alto, California 94305, United States. Electronic address: zcheng@stanford.edu.
Hongguang LiuInstitute of Molecular Medicine, College of Life and Health Sciences, Northeastern University, Shenyang 110000, PR China. Electronic address: simonliu@mail.neu.edu.cn.
Stanford University · USNortheastern University · CNStanford Medicine · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Vittorio Sebastiano · 2007 to 2026
$71.4M
NCI NIH HHS P30 CA124435
6 · The paper itself

Abstract

Spurred by newly developed drug delivery systems (DDSs), side effects of cancer chemotherapy could be reduced by using multifunctional nanoplatforms. However, the facile synthesis of effective DDSs remains a challenge. Here, a six-arginine-tailed anti-epidermal growth factor receptor (EGFR) affibody was employed to easily synthesize the highly reactive oxygen species (hROS)- and trypsin-responsive 11-mercaptoundecanoic acid-modified gold nanoclusters (MUA-Au NCs) for tumor-targeted drug delivery. The polyarginine moiety of affibody sealed methotrexate (MTX)-loaded MUA-Au NCs through charge effect, as well as leaving the rest targeting fragment of the affibody to specifically bind tumor overexpressed EGFR. As the shell of MUA-Au NCs-MTX-Affibody (MAMA), polyarginine chains of affibody could be digested by trypsin, helping to release MTX from MAMA. The released MTX accelerated destroying MUA-Au NCs through inducing the generation of hROS. Specifically targeting EGFR-overexpressed tumors, quickly delivering a sufficient amount of drug to the tumor, subsequently increasing the local MTX and hROS levels, and safely eliminating the biocompatible structure from kidney, endowed MAMA greater treatment effectiveness and lower side effect than chemotherapy, especially in pancreatic cancer due to its high trypsin level. This simply fabricated DDS may find applications in high effective cancer therapy, especially for tumors with high trypsin activity.

Indexed as

Metal NanoparticlesNeoplasmsDrug Delivery SystemsGoldHumansMethotrexateReactive Oxygen SpeciesGoldMethotrexateReactive Oxygen SpeciesCancer therapyDrug deliveryGold nanoclusterReactive oxygen speciesTrypsin

Identifiers

PMID32450093
PMCPMC8006592
OpenAlexW3026284040

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.